CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations

BACKGROUND: Afatinib is a potent, irreversible second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non-small cell lung cancer (NSCLC) patients harboring either common or uncommon EGFR mutations. However, data on its activity...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Liping, Mai, Jianliang, Liang, Weiting, Zou, Qihua, Huang, Caiwen, Lin, Yongbin, Liang, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996125/
https://www.ncbi.nlm.nih.gov/pubmed/36910673
http://dx.doi.org/10.3389/fonc.2023.1094195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996125/
https://www.ncbi.nlm.nih.gov/pubmed/36910673
http://dx.doi.org/10.3389/fonc.2023.1094195

Ejemplares similares